Citations

Showing 10 of 108152 citations.

Automatic detection of calcium phosphate deposit plugs at the terminal ends of kidney tubules
Fernandez, K. A. , Korinek, Mark, Camp, Jon J. , Holmes, David R. , Fernandez, Katrina, Camp, Jon, Lieske, John, Fernandez, K A , Lieske, John C.

Mayo Clinic

Healthcare Technology Letters | October 11, 2019 | Volume: 6 | Issue: 6 | Pages: 271-274

10.1049/htl.2019.0086 | PMID 32038870 Get It

Kidney stones are a common urologic condition with a high amount of recurrence. Recurrence depends on a multitude of factors the incidence of precursors to kidney stones, plugs, and plaques. One method of characterising the stone precursors is endoscopic assessment, though it is manual and time‐consuming. Deep learning has become a popular technique for semantic segmentation because of the high accuracy that has been demonstrated. The present Letter examined the efficacy of deep learning to segment the renal papilla, plaque, and plugs. A U‐Net model with ResNet‐34 encoder was tested; the Letter examined dropout (to avoid overtraining) and two different loss functions (to address the class imbalance problem. The models were then trained in 1666 images and tested on 185 images. The Jaccard‐cross‐entropy loss function was more effective than the focal loss function. The model with the dropout rate 0.4 was found to be more effective due to its generalisability. The model was largely successful at delineating the papilla. The model was able to correctly detect the plaques and plugs; however, small plaques were challenging. Deep learning was found to be applicable for segmentation of an endoscopic image for the papilla, plaque, and plug, with room for improvement.
Oncogenic Drivers of Breast Implant-Associated Anaplastic Large Cell Lymphoma
DeCoster, Ryan , Rinker, Brian, Butterfield, Timothy A. , Vásconez, Henry C., Rinker, Brian D

Mayo Clinic

Plastic & Reconstructive Surgery | October 11, 2019 | Volume: 145 | Issue: 1 | Pages: 195e-196e

10.1097/prs.0000000000006331 | PMID 31609289 Get It

Achilles Heel Molecular Vulnerabilities in Multiple Myeloma Identified From Genome-Scale RNA Interference Screening.
Zhu, Yuan Xiao , Schmidt, Jessica, Shi, Chang‐Xin, Yin, Hongwei , Mousses, Spyro, Stewart, A. Keith , Tiedemann, Rodger E.

Mayo Clinic

Blood | October 11, 2019 | Volume: 114 | Issue: 22 | Pages: 2801-2801

10.1182/blood.v114.22.2801.2801 Get It

Abstract Abstract 2801 Poster Board II-777 To provide a rationale basis for targeted drug development for multiple myeloma patients, we have conducted high-throughput genome-scale RNA interference (RNAi) synthetic lethality studies in human myeloma cell lines (HMCL) to generate a comprehensive map of critical genes and molecular vulnerabilities in human myeloma tumor cells. KMS11 human myeloma cells were screened with a 13,982-oligo library targeting the ‘druggable' genome (6,991 genes) using optimized conditions that resulted in >95% transfection efficiency. Each gene was screened with 2 or more distinct oligos, in duplicate, using a single-siRNA-per-well format, testing >34,000 wells. Replicate high throughput experiments yielded highly reproducible results (R2=0.82). Viability was measured at 96h by ATP-dependent luminescence. Universally lethal siRNA and non-targeted siRNA were employed as controls. The specificity (FDR) of lethal RNAi was evaluated by custom-developed statistical methods based on RNAi result concordancy. From screening, 5.8% of druggable genome siRNA caused statistically relevant reductions in HMCL viability (greater than three standard deviations from control samples treated with non-silencing siRNA, compared with an anticipated rate due to chance of only 0.135%). Of these, two hundred and nineteen genes, targeted by the most lethal siRNA, were forwarded to validation studies. Validation high-throughput RNAi studies, using 4 oligos per gene, were conducted in order to verify target gene vulnerability. Ultimately, seventy two genes were validated as highly critical for myeloma cell survival (each with multiple concordant siRNA hits plus high reproducibility of R2 =0.94). Among top-ranked lethal molecular vulnerabilities in KMS11 myeloma cells we recurrently identified the proteasome (8 PSM subunits were independently identified as highly vulnerable); and BCL2 family member MCL1; both known therapeutic targets, validating a functional genomics approach to target discovery. In addition, a number of novel, equally lethal, molecular vulnerabilities were identified in KMS11 including WEE1, kinetochore complex component KNTC2, the aurora kinases, polo-like kinase 1, a previously uncharacterized DNA methyl transferase, ribonucleotide reductase, ribosomal protein L38, leptin receptor overlapping transcript LEPROT and SLC25A23 (a carrier responsible for mitochondrial adenine nucleotide flux). Various ubiquitous cellular proteins involved in RNA or protein processing (e.g. SF3a, SNW1, SNRPA1, EIF3s8, amongst others) were also identified as non redundant and critical for cellular viability. Thirty nine top-ranked molecular vulnerabilities in KMS11 were evaluated for comparative vulnerability in a second myeloma cell line, JJN3, and in A549 and 293 epithelial cells. A majority were vulnerable in JJN3. While 25 genes proved equally lethal on silencing in A549 and 293 epithelial cells, several, notably including MCL1 and three proteasome subunits, appear differentially susceptible in myeloma cells versus epithelial cells. From this genome scale study, MCL1 ranks third as a target capable of inducing cell death in myeloma cells, highlighting the potent vulnerability of myeloma cell viability to alterations in this anti-apoptosis regulator. Moreover, from active comparative studies of molecular vulnerability in myeloma versus epithelial cell lines, MCL1 as an RNAi target demonstrates perhaps the greatest cytotoxic selectivity between myeloma and epithelial cell lines of all targets examined. Gene expression studies indicate that MCL1 is highly expressed in myeloma tumor cells but is absent or only weakly expressed in human primary somatic tissues. Overall, therefore, from an unsupervised genome-scale screening approach, our data support MCL1 as an optimal Achilles heel molecular target in multiple myeloma, potentially offering greater specificity and deeper cytotoxic effect than proteasome inhibition. Disclosures: No relevant conflicts of interest to declare.
Improved Outcome of CLL Patients with Leukemic Clones Expressing Mutated IGHV May Not Be Due to An Inability to Bind (auto)Antigen In Vivo
Kaufman, Matthew, Yan, Xiao‐Jie , Rassenti, Laura Z., Brown, Jennifer R. , Byrd, John C. , Rai, Kanti R, Ghia, Emanuela M. , Neuberg, Donna , Kay, Neil E. , Rai, Kanti R, Kipps, Thomas J. , Chiorazzi, Nicholas

Mayo Clinic

Blood | October 11, 2019 | Volume: 116 | Issue: 21 | Pages: 2441-2441

10.1182/blood.v116.21.2441.2441 Get It

Abstract Abstract 2441 Background: CLL patients with mutated IGHVs (M-CLL) have clinical outcomes better than patients with unmutated BCRs (U-CLL). It is believed that this difference stems from the fact that somatic mutations have altered the structure of the BCR such that it no longer binds stimulatory (auto)antigens and therefore cannot deliver trophic signals to the leukemic cells. We sought to determine if this belief could be corroborated by analyzing the types (silent vs. conservative vs. non-conservative) and locations (FRs v CDRs) of mutations that occurred in IGHVs of M-CLL clones and then comparing the time to first therapy (TTFT) in patients with different IGHV features. Methods: Using IGMT software, we analyzed the IGHV sequences of 1560 cases and characterized their mutations in several respects: first, if IGHV mutations altered amino acid structure (silent vs. replacement); second, if mutations occurred in CDRs (antigen binding domains) or FRs (scaffolds of the BCR); third, if mutations were conservative or non-conservative (as determined by charge, hydropathy, size). TTFT for patients was correlated with various combinations of the above parameters. Differences in TTFT were estimated by the method of Kaplan and Meier; differences were assessed using the log rank test. Results: First we compared TTFT in patients who had only silent mutations (n=32) to those with no mutations (n=563) and found a trend toward longer TTFT in patients with silent mutations (3.0 vs. 3.6 yrs, p=0.09). Because the statistical significance of this result was likely influenced by the small numbers of clones with only silent mutations, we expanded the group to include IGHVs with replacement mutations of only the conservative type (n=83) since these would be unlikely to havemajor impact on BCR structure. Comparison of this group with those with no mutations for differences in TTFT was significant (3.0 vs. 3.9 yrs, p=0.0007). Furthermore, comparisons of patients with silent plus conservative mutations in FRs only (n=123) versus patients with no mutations showed a clear difference in TTFT (3.0 vs. 4.1, respectively; (p<0.003). In both of the above instances, non-conservative replacement mutations do not have a significantly greater impact on TTFT than the silent plus conservative combination. Conclusions: It is assumed that M-CLL patients have a clinical course superior to U-CLL patients because IGHV somatic mutations change the structure of the M-CLL BCR such that it no longer binds stimulatory antigens. For this theory to be correct, only replacement mutations and in particular non-conservative replacement mutations that would alter amino structure of the IGHV/D/J rearrangements would have relevance. Silent mutations, which by definition do not change amino acid structure, should be irrelevant in this regard, and conservative mutations, which substitute amino acids with similar chemical properties to the original amino acid, would be unlikely to result in major changes in the BCR. Therefore, the fact that the combination of only silent plus conservative mutations, which probably would not result in changes in BCR structure and therefore antigen binding, is associated with a lengthened TTFT militates against a loss of antigen binding as a reason for improved clinical course. Therefore, we suggest that another explanation for the enhanced survival of M-CLL patients should be sought. One possibility is that the cells that have the capacity to mutate their IGHVs are different in origin and/or biologic properties from those that cannot, and these account for the differences in survival between M- and U-CLL patients. (This work was supported NIH grant PO1-CA81534 of the CLL Research Consortium.) Disclosures: Byrd: Genzyme Corporation: Research Funding. Kipps: GlaxoSmithKline: Research Funding.
Evaluation and clinical correlations of bone marrow angiogenesis in myelofibrosis with myeloid metaplasia
Hanson, Curtis A. , Schroeder, Georgene, Tefferi, Ayalew , Mesa, Ruben A. , Rajkumar, S. Vincent

Mayo Clinic

Blood | October 11, 2019 | Volume: 96 | Issue: 10 | Pages: 3374-3380

10.1182/blood.v96.10.3374.h8003374_3374_3380 Get It

Recent observations have underscored the biologic relevance of intratumoral angiogenesis and its potential impact on prognosis. Increased bone marrow angiogenesis has been demonstrated in a variety of hematologic disorders, including multiple myeloma. The extent and prognostic significance of bone marrow angiogenesis in 114 patients with myelofibrosis with myeloid metaplasia (MMM) was investigated. A control group of 44 patients without bone marrow disease, 15 patients with polycythemia vera, and 17 patients with essential thrombocythemia was also studied. Bone marrow microvessel density was assessed by a semiquantitative method, visual microvessel grading, and 2 separate quantitative methods, visual count and computerized image analysis. Angiogenesis estimation by all 3 methods was highly comparable. On visual microvessel grading, a grade 3 or 4 increase in bone marrow angiogenesis was demonstrated in 70% of patients with MMM, 33% of patients with polycythemia vera, 12% of patients with essential thrombocythemia, and 0% of normal controls. In a multivariate analysis, increased angiogenesis in MMM correlated significantly with increased spleen size and was found to be a significant and independent risk factor for overall survival. Increases in marrow angiogenesis correlated with hypercellularity and megakaryocyte clumping. In contrast, these 2 features were inversely proportional to reticulin fibrosis, whereas increases in marrow angiogenesis were independent of reticulin fibrosis. These preliminary findings suggest that neo-angiogenesis is an integral component of the bone marrow stromal reaction in MMM and may provide useful prognostic information and a rationale for the therapeutic investigation of anti-angiogenic agents.
Pharmacokinetic (PK) and Pharmacodynamics (PD) Study of Two Doses of Bortezomib (Btz) in Patients with Relapsed Multiple Myeloma (MM).
Stewart, A. Keith, Sullivan, Dan M. , Mohrbacher, Ann , Chatta, Gurkamal , Shustik, Chaim, Burris, Howard A. , Karol, Michael D., Zannikos, Peter , Reece, Donna , Sullivan, Dan, Lonial, Sagar

Mayo Clinic

Blood | October 11, 2019 | Volume: 108 | Issue: 11 | Pages: 3533-3533

10.1182/blood.v108.11.3533.3533 Get It

Abstract Btz (VELCADE®) is approved for patients (pts) with relapsed MM. This study characterized PK/PD of btz at 2 doses (1.0, 1.3mg/m2) after single- and multiple-dose administration, and evaluated their relationship. 24 pts with relapsed MM and creatinine clearance ≥50mL/min were randomized to btz 1.0 (n=12) or 1.3mg/m2 (n=12) on D 1, 4, 8 and 11 of a 21-D cycle (C). Pts could continue therapy for ≥8 Cs if beneficial. PK/PD samples were drawn at multiple time points on D1 and D11 of C1 and C3 over 48h. Plasma concentrations of btz were similar following administration of 1.0 and 1.3mg/m2; differences in mean plasma Cmax and AUC values were within the degree of intersubject variability (Table). There was a decrease in clearance and an increase in terminal half-life of btz on D11 vs D1 of C1.The volume of distribution of btz suggests extensive peripheral tissue distribution. After single or repeat administration, mean maximum percent inhibition of 20S proteasome activity (vs baseline) in whole blood was 70–84% and 73–83% for the 1.0 and 1.3mg/m2 doses, respectively. The percentage of pts who had >90% inhibition was greater in subsequent doses vs first dose. Reversibility of 20S proteasome inhibition in whole blood was demonstrated. PK/PD modeling revealed an exposure-response relationship, with Emax and EC50 values consistent across study days. These results confirm btz is a potent inhibitor of the 20S proteasome. The efficacy of single-agent btz has been explored and validated in the pivotal phase 2 SUMMIT and phase 3 APEX trials at 1.3mg/m2, and explored in the phase 2 CREST trial at 1.0mg/m2. Complete safety and efficacy data by dose will be presented. Mean±SD PK parameters of btz in plasma 1.0mg/m2 1.3mg/m2 1.0mg/m2 1.3mg/m2 D1/C1 (n=11) D11/C1 (n=12) an=5;bn=11;cn=10;dn=7;en=11;fn=9 Tmax (h) 0.13±0.13 0.11±0.06 0.07±0.03 0.20±0.29 Cmax (ng/mL) 56.7±36.3 112±122 106.2±46.7 88.6±47.6 AUC48h(ng·h/mL) 26.5±12.4 34.6±19.8 82.8±35.9b 82.4±28.6b AUClast (ng·h/mL) 22.6±12.6 31.5±18.6 137±106 122.2±67.4 CL (L/h) 102.1±48.1 111.6±73.6 23.2±17.8 28.0±19.8 Vβ (L) 1976±2498a 2015±2974d 1659±752c 2415±1711 t1/2λz(h) 30.7±44.8a 11.5±12.7d 78.9±50.9c 75.6±49.9 D1/C3 (n=12) D11/C3 (n=12) Tmax (h) 0.12±0.12 0.10±0.05 0.16±0.17 0.10±0.05 Cmax (ng/mL) 66.5±42.6 120.3±70.7 83.9±69.3 114.9±98.3 AUC48h(ng·h/mL) 66.4±24.1 79.4±24.5b 101.6±58.2b 85.2±18.7f AUClast (ng·h/mL) 74.8±35.8 86.0±27.6 227±181 160.7±67.1 CL (L/h) 32.2±19.0 32.1±15.4 15.1±13.9 18.2±9.2 Vβ (L) 1852±951d 2059±1231 3294±2993e 2505±1641 t1/2λz (h) 39.9±14.4d 49.1±34.6 193±169e 108.6±64.8
In-111DAC Is a Novel Technique To Image Multiple Myeloma.
Collins, Douglas A. , Harvey, Mary, Goel, Apollina, Greipp, Philip R., Greipp, Patricia T.

Mayo Clinic

Blood | October 11, 2019 | Volume: 108 | Issue: 11 | Pages: 3488-3488

10.1182/blood.v108.11.3488.3488 Get It

Abstract -Background: An increase in the Vitamin B12 (cobalamin) serum transport protein, transcobalamin II (TCII), has been noted in myeloma (MM) patients (Carmel, Blood. 1978.51(6):1057). Uptake of B12 bound to TCII is regulated by transcobalamin II receptors (TCII-R). Labeled thymidine studies have shown, in vitro, that TCII-R are up-regulated in proliferating malignant cells and correlate with increased incorporation of 3H-thymidine and DNA synthesis (Amagasaki, Blood, 76:1380; 1990). Via cobalt-57 labeled B12 studies, the up-regulation of TCII-R has been demonstrated in solid tumors, in vivo, by Flodh (Int J Cancer, 1968.4(5):694). Indium-111diethylenetriaminepentaacetate adenosylcobalamin (In-111DAC) is a novel radionuclide labeled B12 conjugate that has shown preferential uptake in malignant tissue compared to normal tissue via clinical gamma camera imaging of nude mice with sarcoma xenografts and human patients with various solid tumors (Collins, J Nuc Med, 1997.38(5):717 and Mayo Clin Proc, 2000.75(6):568). Nearly all the human tumors were visualized with In-111DAC and a correlation between increased In-111 uptake and higher invasiveness of the tumor at biopsy was observed. We questioned whether In-111DAC could be utilized to image MM, in vivo in murine models. Methods: In accordance with the Institutional Animal Care and Use Committee, we assessed In-111DAC as an imaging agent for MM in mice with subcutaneous (SQ) MM tumors and mice with systemic MM. 7 week old CB17/scid mice received total body irradiation 150cGy before 1x107 myeloma cells (KAS-6/1-gift of Dr. D.F. Jelinek) were injected SQ between the scapulae. Once tumors reached at least 5mm, both tumor bearing mice and saline control mice without tumor were injected intraperitoneally (IP) with 400 μCi In-111DAC. Mice with SQ tumors were injected with 400 μCi of free In-111 for comparison. Gamma camera images at 15h were followed by CT/SPECT (Single photon emission tomography) images at 18h after IP injection. To evaluate In-111DAC imaging in mice with systemic MM, 7 week old bg-nu-xid mice were injected via tail vein with 1x107 myeloma cells (5TGM1-gift of B.O. Oyajobi). Animals with late stage myeloma (day 23–28) and saline control animals were injected with In-111DAC 400 μCi, and were compared to control animals with late MM, injected with 400 μCi of free In-111. Animals underwent gamma camera and CT/SPECT imaging as in the time-frame above. All animals were sacrificed. Organs and tumors were harvested and weighed. Radioactivity was measured in a NaI scintillation well counter and recorded as cpm/mg. Results: Images and radioactivity measurements in the SQ MM model (KAS-6/1) demonstrated excellent uptake of In-111DAC within the tumor compared to normal tissue and controls. In the 5TGM1 systemic MM model, the spleen is a known sanctuary of MM and displayed especially strong uptake of In-111DAC compared to normal tissue. Conclusion: We report the first murine MM models to be imaged with In-111DAC. Our study affirms that In-111DAC is an excellent imaging agent for MM. In-111DAC imaging could be utilized clinically to complement standard staging studies to assess MM tumor burden in patients at time of diagnosis, relapse, or to assess treatment response; especially in patients with non-secretory disease. Moreover, our study strongly suggests the rationale to exploit TCII-R as a target for MM therapy.
Preliminary Results from a Phase II Study of Lenalidomide Monotherapy in Relapsed/Refractory Aggressive Non-Hodgkin’s Lymphoma.
Wiernik, Peter H. , Lossos, Izidore S. , Justice, Glen R., Pietronigro, Dennis, Takeshita, Kenichi , Ervin‐Haynes, Annette, Zeldis, Jerome B. , Tuscano, Joseph M. , Vose, Julie M. , Habermann, Thomas M.

Mayo Clinic

Blood | October 11, 2019 | Volume: 108 | Issue: 11 | Pages: 531-531

10.1182/blood.v108.11.531.531 Get It

Abstract Background: Lenalidomide (Revlimid®), an immunomodulatory drug (IMiD®), was recently approved in the US for treatment of relapsed/refractory multiple myeloma and myelodysplastic syndromes associated with a deletion 5q[31] cytogenetic abnormality. Lenalidomide also has demonstrated activity in chronic lymphocytic leukemia and cutaneous T-cell lymphoma while thalidomide, a less potent IMiD®, has activity in non-Hodgkin’s lymphoma as both monotherapy and in combination with rituximab. Aim: To assess the safety and activity of lenalidomide monotherapy in subjects with relapsed/refractory aggressive non-Hodgkin’s lymphoma (NHL). Methods: Subjects with relapsed/refractory aggressive NHL following at least 1 prior treatment regimen with measurable disease are eligible. Subjects receive 25 mg lenalidomide orally once daily on Days 1–21 every 28 days and continue therapy for 52 weeks as tolerated or until disease progression. Response and progression are evaluated using the IWLRC methodology. Results: As of July 25, 2006, 32 subjects of a planned 40 have enrolled and 31 have received drug. Twenty-two subjects are currently evaluable for tumor response. The median age of the 22 response-evaluable subjects is 65 (46–83) and 13 are female. Histology is diffuse large B-cell lymphoma [DLBCL] (n=12), follicular center lymphoma grade 3 [FL] (n=3), mantle cell lymphoma [MCL] (n=5) and transformed [TSF] (n=2). Median time from diagnosis to lenalidomide monotherapy is 2.3 (0.7–7) years and median number of prior treatment regimens per subject is 2 (1–6). Seven subjects (32%) exhibited an objective response (2 complete responses unconfirmed (CRu) and 5 partial responses (PR)), 6 had stable disease (SD) for a tumor control rate (TCR) of 59% and 9 progressive disease (PD). Responses were produced in each of the aggressive histologic subtypes studied: DLBCL (3/12), FL (1/3), MCL (2/5) and TSF (1/2). Five of 11 subjects (45%) with 1–2 prior treatment regimens had an objective response, as did 2 of 3 subjects (67%) who had received a prior stem cell transplant. Median time-to-response was 2 months. Grade 3 or 4 adverse events occurred in 18 of 31 (58%) subjects receiving drug. These were predominantly Grade 3 hematological events (neutropenia, thrombocytopenia) with only 4 subjects (13%) experiencing a Grade 4 adverse reaction. Conclusion: Preliminary results indicate that lenalidomide monotherapy is active with manageable side effects in relapsed/refractory aggressive NHL.
Changes in Expert Recommendations and Global Practice Patterns from 2012-2015: Results from an Annually Updated Online Decision Aid for Multiple Myeloma (MM)
Quill, Timothy A., Kumar, Shaji , Lentzsch, Suzanne , Roodman, G. David, Brady, Erik D., Mortimer, Jim, Obholz, Kevin L, Lonial, Sagar , Anderson, Kenneth C.

Mayo Clinic

Blood | October 11, 2019 | Volume: 126 | Issue: 23 | Pages: 2105-2105

10.1182/blood.v126.23.2105.2105 Get It

Abstract Background Clinical practice guidelines for MM list many alternative therapeutic options with an equivalent category of evidence but lack recommendations on the best approaches for individual patient cases. To provide clinicians with expert guidance on treatment options for defined patient scenarios, we developed and updated an interactive, online decision aid that allows users to enter specific disease and patient characteristics, enter their planned treatment, and then compare their choice of therapy with those of an MM expert panel for that scenario. Here we report data from the most recent version (2015) of this tool, capturing changes in expert recommendations and treatment trends for MM over time and evaluating the impact of this online tool on clinical care. Methods Each of 3 annual updates to the tool were developed with input from a panel of 5 MM experts. The individual experts provided treatment recommendations for multiple patient scenarios across the settings of induction therapy, maintenance therapy, and therapy for relapsed/refractory MM. A series of pull-down menus allowed users to select individual patient and disease characteristics identified by experts as important to consider when making treatment choices. These characteristics included: eligibility for autologous stem cell transplantation (for induction therapy only), results of chromosome analysis (cytogenetics/FISH), ECOG performance status, risk of renal insufficiency or peripheral neuropathy, previous therapy and depth of response (for maintenance and relapsed/refractory settings), and cardiac or pulmonary dysfunction (for relapsed/refractory setting). Users were then asked to state their intended management approach for that particular patient scenario. Once completed, recommendations for that scenario from each of the experts were displayed, and users were asked to indicate the impact of the expert recommendations on their treatment choice. Results Expert recommendations spanning the continuum of care were compiled in October 2012, November 2013, and March 2015 for the 3 different MM tool updates. As for earlier versions of the MM tool, each of the experts in the 2015 update provided recommendations for 32 case scenarios for induction therapy, for a total of 160 possible induction recommendations. Comparing overall induction therapy recommendations the use of bortezomib/lenalidomide/dexamethasone was approximately 40% in both 2013 and 2015, whereas the use of carfilzomib-containing regimens increased from 5% to 17%. None of the experts chose regimens with melphalan as induction therapy in 2015. In the relapsed/refractory setting, the use of newer therapeutic approaches continued to grow especially in the setting of patients who did not respond to induction therapy or relapsed within 6 months. For example, in those with prior proteasome inhibitor (PI) therapy, the selection of carfilzomib/lenalidomide/dexamethasone by experts rose from 11% to 38% from 2013 to 2015 with pomalidomide and lenalidomide selected for 20% to 25% of cases in the most recent tool. For prior IMiD and PI, the experts selected a new combination of pomalidomide with a PI (either bortezomib or carfilzomib) and dexamethasone in 55% of the case scenarios in 2015. To date, 170 different clinicians sought guidance on more than 259 patient case scenarios using the 2015 decision support tool. In the subset of cases (n = 104) in which users reported how the tool affected their management of patients with MM, 68% indicated the expert recommendations either confirmed or changed their intended treatment (22% changed; 46% confirmed), whereas 17% indicated that there would be barriers to implementing the expert recommendations, and 5% said they disagreed with the experts' recommendations. Conclusions Expert opinions regarding optimal MM therapy continue to evolve with new evidence. Our data show that interactive online therapy decision aids that provide expert recommendations to clinicians for specific case scenarios can aid decision making and capture practice trends in this rapidly evolving environment. Preliminary data suggest that most clinicians using the online decision aid either confirmed or changed their treatment approaches for specific MM patient case scenarios based on expert recommendations. A detailed and updated analysis of expert and user data will be presented. Disclosures Kumar: Janssen: Consultancy, Research Funding; Novartis: Research Funding; Onyx: Consultancy, Research Funding; Celgene: Consultancy, Research Funding; Takeda: Consultancy, Research Funding; Skyline: Consultancy, Honoraria; BMS: Consultancy; Sanofi: Consultancy, Research Funding. Lentzsch:BMS: Consultancy; Novartis: Consultancy; Axiom: Honoraria; Janssen: Consultancy; Celgene: Consultancy. Lonial:Novartis: Consultancy, Research Funding; Millennium: Consultancy, Research Funding; Onyx: Consultancy, Research Funding; Bristol-Myers Squibb: Consultancy, Research Funding; Janssen: Consultancy, Research Funding; Celgene: Consultancy, Research Funding. Roodman:Amgen: Consultancy; Eli Lilly: Research Funding. Mortimer:AstraZeneca: Other: spouse is an employee of and has equity ownership in.
Long Term Clinical Benefit of Lenalidomide (Revlimid) Treatment in Patients with Myelodysplastic Syndrome without Del 5q Cytogenetic Abnormalities.
Raza, Azra , Reeves, James E., Feldman, Eric J. , Deeg, H. Joachim , Dreisbach, Luke, Schiffer, Charles A. , Shammo, Jamile M. , Klimek, Virginia M., Greenberg, Peter L. , Bennett, John M. , Dewald, Gordon W., Zeldis, Jerome B. , Wride, Kenton, Schmidt, M., Knight, Robert , List, Alan F.

Mayo Clinic

Blood | October 11, 2019 | Volume: 108 | Issue: 11 | Pages: 250-250

10.1182/blood.v108.11.250.250 Get It

Abstract Background: MDSs are clonal hematopoietic stem cell malignancies characterized by cytopenias resulting from ineffective hematopoiesis. A phase 2 study of lenalidomide (MDS-002) demonstrated hematological improvement in patients with MDS without an associated deletion 5q cytogenetic abnormality (List AF, et al. Haematologica2006;91[suppl1]:379[abst 1032]). We now report multicenter results after 〉2 yrs follow-up. Methods: A total of 214 pts with transfusion-dependent anemia were categorized into the following IPSS MDS risk groups after central review of bone marrow morphology, karyotype, and peripheral blood findings: Low/Int-1 (168 [78%]); Int-2/High (8 [4%]); and unclassified (38 [18%]). Patients were unclassified for missing or inadequate marrow studies for central review (morphology [29] or cytogenetic [7]) or other diagnoses (AML [1], atypical CML [1]). Patients were evaluated for frequency and duration of red blood cell transfusion independence (RBC-TI) (IWG criteria), hemoglobin (Hgb) response, and safety. The starting dose of lenalidomide was 10 mg (daily or daily × 3 wks q28d cycle). Results: Overall, 56 (26%) of 214 enrolled patients achieved RBC-TI. Median time to RBC-TI was 5 wks, median duration of RBC-TI response was 41.0 wks (range, 8.0–136.4), and median Hgb increase achieved during RBC-TI was 3.2 g/dL (range, 1.0–9.8). An additional 36 patients experienced a ≥ 50% reduction in RBC transfusions (overall hematological improvement in 92 [43%] patients). Overall, 47 (22%) patients had an abnormal karyotype at baseline and 9 (19%) patients achieved a cytogenetic response (4 complete). The most common drug-related grade 3/4 adverse events (AEs) were neutropenia and thrombocytopenia (25% and 20%, respectively). Deep vein thrombosis occurred in only 2 (1%) patients. The duration of RBC-TI was ≥ 52 weeks in 21 (38%) patients. Among these 21 patients, 14 (67%) did not require a lenalidomide dose reduction during the first 52 weeks of treatment. Analyses of response variables will be presented. Dose-limiting neutropenia/thrombocytopenia was not reported after 52 weeks. The most commonly reported AEs after 52 weeks were mild-moderate diarrhea and fatigue (38% and 29%, respectively). Conclusion: Lenalidomide is an active, well-tolerated treatment in MDS patients with transfusion-dependent anemia that is not associated with a deletion 5q abnormality. The rate of erythroid hematologic improvement and duration of RBC-TI is encouraging and offers a possible alternative to cytokine therapy.